Abstracts tagged "Tocilizumab"

Abstract Number: 1841 • 2019 ACR/ARP Annual Meeting
Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study
Verena Schönau ¹, Jessica Roth ¹, Koray Tascilar ², Jürgen Rech ³, Daniela Schmidt ⁴, Torsten Kuwert ⁴, Filippo Crescentini ⁵, Luigi Boiardi ⁶, Massimiliano Casali ⁷, Annibale Versari ⁸, Giulia Pazzola ⁵, Georg Schett ⁹, Carlo Salvarani ¹⁰ and Francesco Muratore¹¹, ¹Rheumatology Unit, University of Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Nuclear Medicine Unit, University of Erlangen, Erlangen, Germany, ⁵Rheumatology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁶Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁷Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁸Nuclear Medicine Unit, Azienda Unità Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy, ⁹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹¹Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: 18F-FDG-PET/CT is a sensitive and comprehensive technique to diagnose giant cell arteritis (GCA). This technique may be also very useful to test whether vascular…
Abstract Number: 2118 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis
Yushiro Endo¹, Kunihiko Umekita ², Hideki Nakamura ¹, Shoichi Fukui ³, Takahisa Suzuki ⁴, Junya Miyamoto ⁵, Toshimasa Shimizu ¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Tomoki Origuchi ⁶, Akitomo Okada ⁷, Keita Fujikawa ⁸, Akinari Mizokami ⁸, Naoki Matsuoka ⁹, Toshiyuki Aramaki ¹⁰, Yukitaka Ueki ¹⁰, Katsumi Eguchi ¹⁰, Yumi Kariya ², Yayoi Hashiba ¹¹, Toshihiko Hidaka ¹¹, Akihiko Okayama ² and Atsushi Kawakami ¹², ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²University of Miyazaki, Miyazaki, Japan, ³Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Nagasaki, Japan, ⁴Sasebo City General Hospital, Sasebo, Japan, ⁵Nagasaki University Hospital Clinical Research Center, Nagasaki, Japan, ⁶Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁷Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁸JCHO Isahaya General Hospital Department of Rheumatology, Isahaya, Japan, ⁹Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ¹⁰Sasebo Chuo Hospital Rheumatic and Collagen Disease Center, Sasebo, Japan, ¹¹Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ¹²Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: The asymptotic individuals with the human T lymphotropic virus type I (HTLV-I) infection rarely develop adult T cell leukemia/lymphoma (ATL) or HTLV-I–associated myelopathy (HAM).…
Abstract Number: 2745 • 2018 ACR/ARHP Annual Meeting
Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents
Daniela Rossi¹, Irene Cecchi², Elena Rubini³, Massimo Radin⁴, Savino Sciascia⁵ and Dario Roccatello⁶, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy
Background/Purpose: At least 2 biological therapies [tocilizumab (TCZ) and abatacept (ABA)] have been proven to be effective in the management of Giant cell arteritis (GCA)…
Abstract Number: 955 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Infusion Intervals Can be Extended to 5 or 6 Weeks in RA Patients Who Sustained Low Disease Activity By 4 Weeks Interval of Tocilizumab Infusion
Hiroshi Uda and Osamu Saiki, Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: A period of 4 weeks (w) has been recommended as the interval between tocilizumab (TCZ) infusions. The cost of TCZ is very high, which…
Abstract Number: 1249 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab in Patients with Uveitis Refractory to Other Biologic Drugs: A Multicenter Study on 31 Cases
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Inmaculada Calvo², Emma Beltrán-Catalán³, Alfredo Adan⁴, Marina Mesquida⁴, Maria Victoria Hernández⁵, Marisa Hernández⁶, Antonio Atanes-Sandoval⁷, Luis Francisco Linares Ferrando⁸, Olga Maiz Alonso⁹, Ana Blanco¹⁰, Beatriz Bravo¹¹, Gisela Díaz-Cordovés¹², Trinitario Pina¹, Montserrat Santos-Gómez¹ and Miguel A González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Pediatric Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain, ³Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁴Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁶Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁷Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, ⁸Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ⁹Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹⁰Ophthalmology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹¹Pediatrics, Hospital Virgen de las Nieves. Granada, Granada, Spain, ¹²Rheumatology, Hospital Regional Universitario (Carlos Haya). Málaga. Spain., Málaga, Spain
Background/Purpose: To evaluate the clinical response and safety of Tocilizumab (TCZ) in a series of patients with non-infectious uveitis refractory to other biologic drugs.Methods: Multicenter…
Abstract Number: 1472 • 2013 ACR/ARHP Annual Meeting
Discontinuation Rates Of Tocilizumab Therapy In Rheumatoid Arthritis Patients In a Nonacademic Clinical Setting
Jaishree Manohar¹ and Charles H. Pritchard², ¹Rheumatology, Drexel University College of Medicine, Sarasota, FL, ²Rheumatology, Drexel University College of Medicine, Willow Grove, PA
Background/Purpose: Tocilizumab(TCZ) and other biologics are expensive and switching between them is difficult. The goal of this retrospective chart analysis is to identify the discontinuation…
Abstract Number: 1447 • 2013 ACR/ARHP Annual Meeting
Success Rate Of 5-Or-More-Week Extended-Interval Therapy With Tocilizumab In Rheumatoid Arthritis Patients In Routine Practice
Masahiro Minoda¹, Kazuki Yoshida^1,2, Hideto Oshikawa¹, Hiroto Nakano¹, Naoho Takizawa¹, Kenichiro Tokunaga¹, Tatsuo Kobayashi¹, Mitsumasa Kishimoto³ and Kazuo Matsui¹, ¹Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ²Harvard School of Public Health, Boston, MA, ³Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Tocilizumab retreatment is effective and well tolerated in patients with rheumatoid arthritis whose disease activity flared after stopping the therapy. Therefore, reducing tocilizumab dose…
Abstract Number: 1428 • 2013 ACR/ARHP Annual Meeting
The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA)
Alan Kivitz¹, Ewa Olech², Michael A. Borofsky³, Beatriz M. Zazueta⁴, Federico Navarro-Sarabia⁵, Sebastião C. Radominski⁶, Joan T. Merrill⁷, Chris Wells⁸, Sunethra Wimalasundera⁸, Wendy Douglass⁸ and Janet E. Pope⁹, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, ³Clinical Research Center of Reading, Reading, PA, ⁴Reumatologia, Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, ⁵Rheumatology, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Roche, Welwyn Garden City, United Kingdom, ⁹Rheumatology, St Joseph Health Centre, London, ON, Canada
Background/Purpose: The BREVACTA study assessed the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) in pts with moderate to severe RA who had an inadequate response…
Abstract Number: 464 • 2013 ACR/ARHP Annual Meeting
The Efficacy and Safety Of Tocilizumab Subcutaneous Versus Tocilizumab Intravenous, In Combination With Traditional Dmards In Patients With RA At 49 Weeks (SUMMACTA)
Gerd Burmester¹, Andrea Rubbert-Roth², Alain G. Cantagrel³, Stephen Hall⁴, Piotr Leszczynski⁵, Daniel Feldman⁶, Madura J. Rangaraj⁷, Georgia Roane⁸, Charles L. Ludivico⁹, Eduardo F. Mysler¹⁰, Chris Wells¹¹, Melanie Bennett¹¹ and Ivana Vranic¹¹, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Klinikum der Universität zu Köln, Köln, Germany, ³Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁴Emeritus Research, Malvern, Australia, ⁵Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁶Rheumatology, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁷Arthritis & Diabetes Clinic, Inc., Monroe, LA, ⁸Rheumatology Associates of South Carolina, Charleston, SC, ⁹East Penn Rheumatology Associates, PC, Bethleham, PA, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina, ¹¹Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: The efficacy and safety of subcutaneous tocilizumab (TCZ SC) were demonstrated in a 24 week (wk) randomized clinical trial (SUMMACTA). The cumulative safety, immunogenicity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].